Kornimate/medical-research-clean huggingface dataset:
cardiac coherence combined with personal physical activity in patients with cancer

Conditions: Physical Activity; Cancer; Hematologic Diseases

Summary: apacche (adapted physical activity and cardiac coherence in hematologic patients) study investigates effects of heart rate variability biofeedback training, combined with classical adapted physical activity, on health-related quality of life in patients previously treated for hematologic malignancies. it is a prospective, randomized clinical trial from university hospital of reunion island. the main objective is evaluated with qlq-c30 survey score differences.

hematologic malignancies are aggressive cancers with significant long-term effects on physical and psychological health, due to the disease itself or aggressive treatments. physical activity, with specific treatments, improves physical and psychological health in solid tumors patients. however, in hematologic malignancies, there is unsatisfactory quality of evidence that physical activity alone improves the various dimensions of quality of life. recent studies on heart-brain connections suggest that a high level of coherence in the heart rate variability may induce psychophysiological positive effects. cardiac coherence is reached when the heart rhythm pattern becomes sine-wave-like at a frequency around 0.1 hz. this status can be increased by the mean of deep and slow breathing control and/or positive emotions. by using a heart rate variability biofeedback training, previous studies have shown effects on physiological variables such as reduction of blood pressure or increase of vagal heart rate control, and also on psychological variables such as reduction of stress, anxiety, and depression. the apacche protocol investigate if cardiac coherence biofeedback training, associated with an adapted physical activity program, can improve health related quality of life in adult hematologic patients. 70 patients are randomly assigned to receive either ten sessions of cardiac coherence biofeedback (cc-bf) and the adapted physical activity program (apa) or just apa. both interventions are conducted simultaneously over 12 weeks, with 10 sessions of cc-bf (45mn) weekly and 24 sessions of apa (1h30) bi-weekly. data are collected at enrollment(t1), at 6 weeks (t2), at intervention ending at 12 weeks (t3) and after a 24 weeks follow-up (t4).

Eligibility criteria:
inclusion criteria: * all patients, previously treated and in remission for an hematologic malignancy, in whom apa is indicated. * adult patients aged 18-65 yo * followed at south university hospital of la réunion island * previously treated for hematologic malignancy, and in remission (complete or partial) * 6 months or less since last treatment * hemoglobin steady ≥ 90g/l * in whom apa is prescribed * ability to give oral informed consent * french understanding exclusion criteria: * with contraindication for apa * under anti-arhythmic or beta-blocker drugs * cardiac insufficiency (left ventriculi ejection fraction less than 40%) * participation in another trial
intraarterial stem cells in subacute ischemic stroke

Conditions: Ischemic Stroke; MCA Infarction

Summary: stroke is a leading cause of morbidity and mortality.acute ischemia causes irreversible damage to neurons and glial cells, leading to functional deficits and chronic sequelae with variable degrees of spontaneous recovery of function. stem cells have been shown to enhance recovery through multiple immunomodulatory effects, neoangiogenesis and neurogenesis. we conducted a prospective randomised end observer blinded study to evaluate primarily the safety of intraarterial autologous stem cells delivered to ipsilateral middle cerebral artery in acute and subacute stroke patients (0-15 days post ictus).secondarily we aimed to evaluate the outcome on the basis of clinical evaluation and follow up imaging

1. this study was done over a period of one and a half years from july 2015 to december 2016. a total of 229 patients who presented with acute middle cerebral artery stroke and admitted at post graduate institute of medical education and research were evaluated for recruitment into this study. 2. participants who satisfied the inclusion criteria were randomized at 1 week into control and stem cell infusion test group within 15 days of stroke onset. 3. investigators evaluated 20 patients, with 10 each in control and stem cell infusion test group. 4. participants in the test group were infused autologous bone marrow mononuclear cells through intraarterial route using a microcatheter which was placed in proximal ipsilateral m1 segment of mca. participants in the control group did not receive stem cell therapy. rest of the pharmacological treatment and physiotherapy were similar in both groups for the period of 6 months. 5,participants were evaluated with clinical and radiological follow up at 6 months.

Eligibility criteria:
inclusion criteria: requires presence of all of the following 1. age range 20-80 years symptoms 2. signs of clinically definite mca stroke (0 to 14 days post ictus) 3. national institute of health stroke scale (nihss)\> 7, 4. stroke clinically and on imaging conforming to the mca territory, 5. recanalization/patency of involved m1 segment of mca on imaging 6. patency of carotid arteries for intra-arterial access of cerebral circulation exclusion criteria: requires presence of any of the following 1. cerebral hemorrhage on ct/mri 2. imaging evidence of m1-mca segment complete occlusion 3. hemodynamic instability 4. known defect of clotting or platelet function 5. severe co-morbidity precluding intra-arterial intervention 6. hepatic or renal dysfunction 7. pregnant patients 8. patient likely to be unavailable for follow-up 9. patients with evidence of chronic illness or advanced cancer 10. patient already dependent in activities of daily living before the present acute stroke i.e. pre stroke mrs \>3 11. refusal to give informed consent
effects of verbal instructions on fear extinction and extinction retrieval

Conditions: Anxiety Disorder

Summary: the goal of this study is to examine if verbal instructions can improve fear extinction learning and extinction retrieval in patients with anxiety disorders (ad) and healthy controls.

patients with anxiety disorders (ad) and highly anxious individuals show accelerated fear conditioning and diminished fear extinction learning (duits et al., 2015). the aim of the current study is to investigate how verbal instructions impact fear extinction learning and extinction retrieval in ad patients and healthy controls. using a 3-day fear conditioning paradigm, fear acquisition will take place on the first, extinction training on the second, and extinction retrieval and reinstatement on the third day (i.e., all phases are on consecutive days). part of the participants will receive explicit instructions such that the unconditioned stimulus (ucs) won't be presented anymore, either before and/or after extinction training. participants will be randomly assigned to four conditions: (1) no explicit instructions at all, (2) explicit instructions before extinction, (3) explicit instructions after extinction or (4) explicit instructions before and after extinction.

Eligibility criteria:
inclusion criteria: * for the patient group: dsm-5 anxiety disorder diagnosis via a structured clinical interview for diagnosing mental disorders (dips) * for the healthy controls: no psychological disorder according to the mini-dips exclusion criteria: * smoking * alcohol abuse * drug consumption * current and chronic physical and neurological diseases * for the patient group: anxiety not the primary diagnosis, psychological comorbidities e.g. schizophrenia, bipolar disorder, mental retardation, acute drug or alcohol addiction, personality disorder, currently in psychotherapy * for the healthy controls: a diagnosis of psychological disorder at any point in life, ever been in psychotherapy, current and/or regular intake of medicine (incl. psychopharmaceutic medicine), current or past cognitive or neurological disorder * for women: pregnancy, nursing period * previous experience with fear conditioning paradigm

Keywords: anxiety disorders fear extinction fear conditioning instructions contingencies
priming motor learning through exercise in people with spinocerebellar ataxia

Conditions: Spinocerebellar Ataxia Type 1; Spinocerebellar Ataxia Type 2; Spinocerebellar Ataxia Type 3; Spinocerebellar Ataxia Type 6; Spinocerebellar Ataxia Type 7

Summary: prime-ataxia is a randomized controlled trial that aims to determine the feasibility and efficacy of an 8-week telehealth intervention of high intensity aerobic exercise prior to balance training compared to an 8-week telehealth intervention of low intensity exercise prior to balance training in people with spinocerebellar ataxias (scas). the investigators additionally aim to explore changes in motor skill learning on a novel motor skill task in a sub-group of participants pre and post intervention.

the prime-ataxia randomized controlled trial involves 2 groups of participants (n=20). one group (high intensity exercise + balance) will receive high intensity aerobic exercise followed by balance training, and another group (low intensity exercise + balance) will receive low intensity exercise (stretching, warm up exercises) followed by balance training. both groups will undergo four remote assessments (2 baseline assessments, a mid-intervention assessment, and a post-intervention assessment). a subset of individuals (n=12) from both groups will undergo an in-person assessment on a novel motor task, along with digital posturography assessment of standard functional assessments of mobility and balance at baseline 1 (week 0), and post-intervention (week 16).

Eligibility criteria:
inclusion criteria: 1. between the ages of 18 to 85 years 2. genetically confirmed diagnosis of sca1, 2, 3, 6, and 7 3. scale for ataxia rating and assessment (sara) score between 8-25/40, capturing mild-moderate disease 4. able to walk with/without assistive device 5. successful completion of physical activity readiness questionnaire (par-q) to confirm no medical contraindications to exercise 6. care partner availability during assessments and/or intervention pending balance scores exclusion criteria: 1. severe non-ataxic motor symptoms such as dystonia, tremor, or parkinsonism, measured by inventory of non-ataxia signs (inas) 2. peripheral sensory loss (as confirmed with monofilament or clinical proprioceptive testing) 3. severe visual complications associated with ataxia (i.e., spontaneous nystagmus, retinal or optic nerve involvement, especially in sca7) defined as as have a score on the snellen visual acuity test = 20/200 - 20/400, or a visual field of 20 degrees of less. 4. musculoskeletal injury that would prevent participation in an exercise program 5. other concurrent disease of the cerebellum (e.g. stroke, multiple sclerosis) 6. cardiac/pulmonary conditions that would affect participants ability to participate exercise program 7. currently engaged in \>3 week moderate-high intensity aerobic exercise and/or balance training

Keywords: aerobic exercise balance motor learning neurorehabilitation telehealth spinocerebellar ataxia physical therapy rehabilitation cerebellum high intensity aerobic exercise
evaluation of preoperative endobronchial ultrasound (ebus) in non small cell lung cancer (nsclc)

Conditions: Non Small Cell Lung Cancer

Summary: this study aims to assess both the role and cost-effectiveness of ebus in preoperative non small cell lung cancer staging. this controlled multicentric study will be conducted in 22 centers in france. the study design includes two prospective phases. in phase 1, one investigator in each center will prospectively be evaluated for its ability to perform ebus, with a required goal of 9 informative samplings out of 10 consecutive patients. the phase 2 will include the medico-economic assessment of the technique in the preoperative setting. a maximum of 420 patients for each phase is forecasted.


Eligibility criteria:
inclusion criteria: * adult patients over 18 * non small cell lung cancer histologically or cytologically proved * clinical stage iiia * anatomically and functionally resectable exclusion criteria: * uncorrected bleeding disorders * absence of lymphadenopathy superior to 1cm in small axis at ct scan * contraindication to bronchoscopy * extrathoracic or intrathoracic metastasis * respiratory function tests not compatible with curative resection of lung cancer

Keywords: non-small cell lung cancer mediastinal lymph node resectable ebus stage iiia significant mediastinal lymph node at thoracic ct scan
tacrolimus (fk506) p-iii, open-label study in refractory ulcerative colitis patients

Conditions: Ulcerative Colitis

Summary: patients with severe refractory ulcerative colitis (uc) or those who received placebo in study f506-cl-1107 will receive tacrolimus for a maximum of 12 weeks. safety and efficacy will be evaluated.

patients with severe refractory ulcerative colitis (uc) or those who received placebo in study f506-cl-1107 study can participate in this study. patients will receive tacrolimus for a maximum of 12 weeks in an open-label study manner. improvement of disease activity index (dai) score and other efficacy scores will be evaluated during the drug administration period.

Eligibility criteria:
inclusion criteria: * severe refractory uc patients who meets the following criteria * disease activity: more than 6 times of stool a day, bloody stool, moderate to severe endoscopic finding * steroid resistant or dependent or * moderate to severe refractory uc patients who participated and received placebo in f506-cl-1107 study exclusion criteria: * mild or fulminant type * renal failure patients, hepatic failure patients * patients taking 6-mercaptopurine, cyclosporin or other immunosuppressants within 12 weeks prior to entry * patients who received lcap or gcap within 2 weeks prior to entry * patients who changed the dose of steroid or started steroid within 2 weeks prior to entry * patients who changed the dose of steroid or started steroid within 1 week prior to entry in case they received more than 40 mg/ day or 1mg/kg/day of steroid just before the study

Keywords: ulcerative colitis tacrolimus fk506 treatment outcome
paresthesia-free fast-acting subperception (fast) study

Conditions: Chronic Pain

Summary: study to evaluate the effectiveness of fast-scs (fast-acting paresthesia-free therapy) and additional scs therapy options in patients with chronic pain using boston scientific wavewriter scs systems.


Eligibility criteria:
key inclusion criteria: * chronic pain (predominantly neuropathic) of the trunk and/or limbs for at least 6 months with back pain greater or equal to leg pain. * 22 years of age or older when written informed consent is obtained * able to independently read and complete all questionnaires and assessments provided in english * signed a valid, irb-approved informed consent form (icf) provided in english key exclusion criteria: * any pain-related diagnosis or medical/psychological condition or external factors that, in the clinician's best judgment, might confound reporting of study outcomes * significant cognitive impairment that, in the opinion of the investigator, would reasonably be expected to impair the study candidate's ability to participate in the study * breast-feeding or planning to get pregnant during the course of the study or not using adequate contraception * participating, or intends to participate, in another clinical trial that may influence the data that will be collected for this study

Keywords: spinal cord stimulation
connective tissue growth factor in patients with neovascular age related macular degeneration

Conditions: Wet Macular Degeneration

Summary: age-related macular degeneration (amd) remains a leading cause of blindness in united states and can be broadly divided into two forms: non-neovascular amd (nnvamd) and neovascular amd (nvamd) amd. among the several mechanisms underlying amd, hypoxia and oxidative stress have been implicated and cause upregulation of several signaling proteins. about 20% of patients with nnvamd develop choroidal neovascularization and hence convert to nvamd. upregulation of vascular endothelial growth factor (vegf) plays a critical role in conversion from nnvamd to nvamd. connective tissue growth factor (ctgf) is a polypeptide that has been shown to be overexpressed in various fibrotic disorders, suggesting its involvement in scarring. after the development of choroidal neovascularization, subretinal fibrosis may occur and result in permanent reduction of vision. an important question is, does ctgf contribute to subretinal fibrosis. an important first step in addressing this question is to determine if ctgf levels are increased in the eyes of patients with nvamd and this is the objective of this study. the investigators plan to measure levels of connective tissue growth factor (ctgf) in the aqueous humor of patients with neovascular age-related macular degeneration and compare to controls. levels of vegf will be measured as a positive control.


Eligibility criteria:
inclusion criteria: * age \>/= 18 years * willing to sign informed consent and authorization of use and disclosure of protected health information * for study group: patients must have a clinical diagnosis of nvamd * for control group: patients undergoing vitrectomy for macular hole, macular pucker, or vitreomacular traction, vitreous floaters or another condition unrelated to scarring. exclusion criteria: * subjects with a retinal condition other than nvamd in which scarring may occur such as proliferative vitreoretinopathy or retinal detachment.
clinical and laboratory patterns of pediatric gross hematuria

Conditions: Hematuria

Summary: study the demographic, clinical, laboratory and etiological profile of children with gross hematuria and trace the outcome of these patients for at least 3 months follow up.

gross hematuria is a scary but common medical problem in children. this condition is considered one of the most important manifestations of kidney and urinary tract diseases. when colour of urine with blood is reddish, brown or dark or cola coloured, the condition is called as macroscopic (gross) hematuria. however, blood in urine may not always be visible to the naked eye, when it is called as microscopic hematuria. this condition can be transient, intermittent or persistent and it may be symptomatic or asymptomatic. hematuria originating from glomerulus is almost never bright red but usually brown, tea coloured or cola coloured. in contrary, hematuria originating from the lower urinary tract is usually pink or red in colour. pigments and other compounds in certain foods (including beets, berries, and food colourings) and drugs (sulfonamides, rifampicin, ibuprofen, salicylates, phenothiazines, metronidazole, phenolphthalein, chloroquine, deferoxamine, etc.) can change the colour of urine that is called false hematuria. the causes of hematuria are very diverse, ranging from simple urinary tract infections with rapid recovery to mechanical trauma and severe glomerulonephritis with rapid decline in kidney function, it is essential to recognize the underlying disease and treat it accordingly. the causes of gross hematuria may be categorized to whether the hematuria is glomerular or non-glomerular in origin. this distinction can be determined by microscopic examination of the urine to detect dysmorphic or monomorphic red blood cells in glomerular and non-glomerular hematuria, respectively. although glomerular diseases are nearly always associated with some degree of hematuria, gross hematuria as a presenting manifestation is more commonly encountered with acute poststreptococcal glomerulonephritis, lupus nephritis and iga nephropathy. non-glomerular hematuria is most often associated with renal stones, tumours, idiopathic hypercalciuria, bacterial or viral urinary tract infection, urolithiasis and structural anomalies of the urinary tract. it is essential to establish the cause and origin of hematuria in each case through proper history, clinical features and investigations including laboratory, radiological studies and/or percutaneous renal biopsy in some cases. but at the same time, it is important that the pediatrician is aware what any of such procedures might be helpful in establishing a proper diagnosis.

Eligibility criteria:
inclusion criteria: * lnvestigators will include all patients complaining of gross hematuria between the ages of 1 month up to 16 years. exclusion criteria: * children with external perineal or genital region bleeding which may falsely cause presence of blood in urine samples. * patients whose legal guardians will refuse participation in the study. * patients with follow up for less than 3 months.

Keywords: gross hematuria
evaluation of the effect of intra-ligamentary injection of diclofenac potassium versus articaine on anaesthetic efficacy in mandibular molars with symptomatic irreversible pulpitis.

Conditions: Teeth With Acute Irreverseble Pulpitis

Summary: this study aims to assess the effect the intraligamentary injection of diclofenac potassium versus articaine 4% on the anaesthetic efficacy \& intensity of intraoperative \& postoperative pain during single visit root canal treatment in patients with symptomatic irreversible pulpitis in mandibular molar teeth


Eligibility criteria:
inclusion criteria: * systemically healthy patient (asa i or ii). * mandibular posterior teeth with: preoperative sharp pain, absence or slight widening in the periodontal ligament (pdl), vital response of pulp tissue to cold pulp test. * patients who agree to provide written consent and the patients able to understand the pain scale and attend for recall appointments exclusion criteria: 1. patients allergic to anesthetic solutions \& other nsaids. 2. pregnant or nursing females. 3. patients having significant systemic disorder (asa iii or iv). 4. gastrointestinal disorders. 5. if the initial diagnosis revealed pain in more than one tooth. 6. hemostatic disorders or anti-coagulant therapy during the last month. 7. consumption of opioid or non-opioid analgesics or nsaids during the last 12 hours before treatment. 8. teeth that have: i. periodontal involvement (with pocket depth greater than 5mm, associated with swelling or fistulous tract, or greater than grade i mobility). ii. no possible restorability. iii.signs of pulpal necrosis; associated sinus tract or swelling. -
acute kidney injury in patients with sickle cell disease

Conditions: Sickle Cell Disease; Kidney Injury; Kidney Diseases; Kidney Disease, Chronic

Summary: patients with sickle cell disease may be at risk for acute kidney injury (aki)during sickle cell crisis (pain or acute chest syndrome). this study will evaluate the role of hemolysis during scd crisis on the development of aki and the role for monitoring urine biomarkers during an admission for crisis and during well clinic follow-up.

patients admitted to the hospital for acute chest syndrome or vaso-occlusive pain events may consent to participate in this study. patients will consent to daily blood and urine collection during their hospitalization and during well clinic visits. each am, participants will have blood and urine collected, processed, and strored for future analysis of hemolytic markers and biomarkers of kidney injury. patients will also have strict urine output recorded. acute kidney injury (aki) will be defined by the current kdigo definition based on either a rise in serum creatinine or decline in urine output. patient medical course will be reviewed to determine interventions and outcomes of their admission based on the development of aki.

Eligibility criteria:
inclusion criteria: * patients with hbss or sb0 thalassemia admitted for vaso-occlusive pain crisis or acute chest syndrome * able to sign informed consent exclusion criteria: -